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Oligodendrocyte RasG12V Expressed in its Endogenous Locus 
Disrupts Myelin Structure Through Increased MAPK, Nitric 
Oxide, and Notch Signaling
Haley E. Titus1,2, Alejandro López-Juárez1,2, Sadiq H. Silbak1, Tilat A. Rizvi1, Madeleine 
Bogard1, and Nancy Ratner1,*
1Division of Experimental Hematology and Cancer Biology, Cincinnati Children's Hospital Medical 
Center, Cincinnati, OH, 45229, USA
Abstract
Costello syndrome (CS) is a gain of function Rasopathy caused by heterozygous activating 
mutations in the HRAS gene. Patients show brain dysfunction that can include abnormal brain 
white matter. Transgenic activation of HRas in the entire mouse oligodendrocyte lineage resulted 
in myelin defects and behavioral abnormalities, suggesting roles for disrupted myelin in CS brain 
dysfunction. Here we studied a mouse model in which the endogenous HRas gene is conditionally 
replaced by mutant HRasG12V in mature oligodendrocytes, to separate effects in mature 
myelinating cells from developmental events. Increased myelin thickness due to decompaction 
was detectable within one month of HRasG12V expression in the corpus callosum of adult mice. 
Increases in active ERK and Nitric Oxide (NO) were present in HRas mutants and inhibition of 
NO synthase (NOS) or MEK each partially rescued myelin decompaction. In addition, genetic or 
pharmacologic inhibition of Notch signaling improved myelin compaction. Complete rescue of 
myelin structure required dual drug treatments combining MAPK, NO or Notch inhibition; with 
MEK + NOS blockade producing the most robust effect. We suggest that individual or 
concomitant blockade of these pathways in Costello syndrome patients may improve aspects of 
brain function.
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Introduction
Rasopathies are genetic disorders in which patients are heterozygous for germline mutations 
in genes of the Ras-MAPK signaling pathway (Tidyman and Rauen 2016). Costello 
syndrome (CS) is a rare gain of function Rasopathy caused by a heterozygous mutation of 
*Corresponding Author: Nancy Ratner, Nancy.Ratner@cchmc.org, Mailing address: 3333 Burnet Ave., Cincinnati Children's 
Hospital, Cincinnati, OH, 45229-7013, Telephone: 513-636-9469, Fax: 513-803-1083.
2These authors contributed equally to this work.
Author Contributions: H.T.M. and A.L.J. performed experiments, analyzed data, and drafted the manuscript. T.R. assisted with 
perfusions. S.H.S. and M.B. quantified g-ratios and myelin decompaction from electron micrographs; S.H.S. also performed statistical 
analyses. N.R. designed the project, aided in data analysis and interpretation, and edited the manuscript and figures.
HHS Public Access
Author manuscript
Glia. Author manuscript; available in PMC 2018 December 01.
Published in final edited form as:













the HRAS gene on chromosome 11p15.5, which results in neurocognitive impairment and 
relative macrocephaly (Quezada and Gripp 2007). Other manifestations include facial 
dysmorphism, growth retardation, gastrointestinal, skin and musculoskeletal anomalies, 
cardiovascular abnormalities, and tumor predisposition. Most CS patients show HRASG12S 
mutation, which causes psychomotor delay with low intelligence and developmental index 
scores (Zampino et al. 2007). Furthermore, a rare HRASG12V mutation was linked to a 
severe form of CS (Aoki et al. 2005). All these mutations increase HRAS-GTP and 
activation of downstream signals, including activation of the MAPK signaling pathway that 
results in phosphorylation of the kinases MEK1/2 and ERK1/2 (Quezada and Gripp 2007). 
Correlating with severe patient phenotypes, the G12V mutant of HRAS displays the lowest 
GTPase activity among known HRASG12 mutations (Colby et al. 1986), and is a 
predominant mutation in human cancers (Aoki et al. 2005).
Mental retardation, macrocephaly and variable cognitive delay are frequent in CS patients 
(Axelrad et al. 2007; Gripp et al. 2010; Rauen 2007). Moreover, synaptic plasticity may be 
affected in CS patients (Mainberger et al. 2016). At cellular level, brain neurons and 
astrocytes have been studied in models of CS. Increased HRAS-GTP promotes production of 
cortical neurons with morphological deficits (Rooney et al. 2016). Human induced 
pluripotent stem cells from RASG12S CS patients differentiate to astroglia more rapidly 
than wild type cells. Additionally, RASG12S cells show abnormal astrocyte-to-neuron 
signaling, as do astrocytes in an astrocyte-driven RASG12V mouse model (Krencik et al. 
2015). Interestingly, MRI studies have shown brain white matter (WM) abnormalities in CS 
patients, suggesting that delayed myelination and/or abnormal myelin contribute to CS 
developmental delays (Delrue et al. 2003). These studies, together with research relating 
defective oligodendrocyte function with mental illness (Haroutunian et al. 2014), suggest 
that hyperactive RAS in myelinating cells may contribute to CS pathology.
Myelin sheaths are plasma membrane projections of oligodendrocytes that spirally wrap 
axons and myelin layers become compacted, increasing axon conduction velocity (Bauer et 
al. 2009; Franklin and Gallo 2014). The Ras-MAPK pathway kinases MEK and ERK 
regulate several aspects of developmental, injury-induced and in vitro oligodendrogenesis as 
well as regulate the number of myelin wraps produced by normal oligodendrocytes (Fyffe-
Maricich et al. 2011; Fyffe-Maricich et al. 2013; Guardiola-Diaz et al. 2012; Ishii et al. 
2013; Xiao et al. 2012). In contrast, mice expressing the Ras-activating HRasG12V allele in 
cells of the oligodendrocyte lineage starting at embryonic day 12.5, exhibit myelin 
decompaction at intraperiod lines in adult mice. These mutants show hyperactive behavior 
and increased response to startle, correlating with the presence of abnormal myelin (Mayes 
et al. 2013). These results are consistent with the hypothesis that defects in myelinating cells 
contribute to phenotypes in Rasopathies.
Elevated Ras signaling through MEK/ERK can increase reactive oxygen and nitrogen 
species (ROS) (Heimfarth et al. 2013), and in CNPase;HRasG12V mice, nitric oxide (NO) 
mediates myelin decompaction (Mayes et al. 2013); HRasG12V-expressing white matter 
showed elevated NO synthases (NOS) and ROS, and blockade of NOS rescued aberrant 
behavior and myelin compaction. NO signaling inhibition also rescued myelin decompaction 
caused by inactivation of the Ras-GTP inhibitor Nf1 in oligodendrocytes and, interestingly, 
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blocking NO production rescued abnormally hyperactive Notch signaling (López-Juárez et 
al. 2017). Cell-cell interactions through Notch signaling negatively regulate oligodendrocyte 
maturation and myelin wrapping (Wang et al. 1998; Watkins et al. 2008). While a direct link 
between RAS and Notch in mOLs has not been identified, in other systems multiple levels 
of crosstalk between these signaling pathways are known (Sundaram 2005). Ras-GTP can 
act upstream of Notch signaling and the Notch pathway can feedback to antagonize the Ras 
pathway (Baumgart et al. 2015). Here, we aimed to delineate effects downstream of 
HRasG12V mutation in mature oligodendrocytes (mOLs).
A limitation of transgenic HRasG12V mice to model the CS brain is that transgenic 
expression of activated RAS often fails to accurately model disease, due to altered levels, 
timing and/or strength of activating alleles in specific cell types (Di Nicolantonio et al. 2008; 
Sarkisian et al. 2007; To et al. 2008). For example, CNPase;HRasG12V was expressed early 
in development, in immature and mature oligodendrocytes, and lacks normal genomic 
regulation (Mayes et al. 2013). To better mimic human HRasG12V mutation in CS, we 
conditionally substituted the endogenous wild type HRas with the mutant HRasG12V (Chen 
et al. 2009) in mature oligodendrocytes (mOLs). We found that myelin decompaction occurs 
rapidly after oligodendrocyte HRasG12V hemizygous expression. Compaction is improved 




All mouse studies were approved by The Cincinnati Children’s Hospital Research 
Foundation, Institutional Animal Care and Use Committee (IACUC). Mice were housed in a 
temperature- and humidity- controlled vivarium on a 12-hour light-dark cycle with free 
access to food and water. Adult (<8 weeks old) male and female mice were used for 
experimentation.
Mouse Strains
See description in table below. All mice were maintained on a C57Bl/6 background. Mice 
were genotyped by PCR as previously described (references).
Tamoxifen Injections
Tamoxifen (Sigma-Aldrich) (100 µL; ~75mg/kg of body weight) in sunflower seed oil was 
administered I.P. twice daily for 4 consecutive days. Treatment was performed at 8 week of 
age in littermate WT and mutant mice, of both sexes. No genotype- or sex-dependent 
changes in body weight were observed.
Tissue Processing
Mice were anesthetized and perfused with 0.9% saline followed by ice cold 4% 
paraformaldehyde. Tissues were removed, post-fixed in 4% paraformaldehyde overnight and 
sectioned using a vibratome (Leica) or transferred to 20% sucrose for subsequent frozen 
sectioning.
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Cryostat or vibratome sections were processed for immunohistochemistry using antibodies 
for markers; Rabbit anti-pERK (1:200; Cell Signaling) and Mouse anti-APC (CC1 1:300, 
Calbiochem). Fluorescent secondary antibodies (donkey anti-rabbit conjugated to Cy3 and 
donkey anti-mouse conjugated to Cy5, Invitrogen, Carisbad, CA) were used at 1:300 
dilution. Fluoromount G was used to mount fluorescent sections.
Image Analysis
Fluorescent images were captured on a Nikon C2 Confocal microscope using a 20× 
objective (2× Zoom for 40×) with lasers (405, 488, 561). Cell counting was performed using 
an ImageJ micromanager plugin and Imaris Software.
Electron Microscopy
Wild type and experimental littermate mice were processed at the same time to minimize 
myelin structure artifacts caused in processing. Mice were perfused with 4% 
paraformaldehyde/2.5% glutaraldehyde and post–fixed in the same fixative overnight. The 
corpus callosum was dissected and transferred to 0.175M cacodylate buffer, osmicated, 
dehydrated and embedded in Embed 812 (Ladd Research Industries). Ultrathin sections 
were stained in uranyl acetate and lead citrate, and then imaged on a Hitachi Model H-7600 
transmission electron microscope.
Myelin Analysis
To quantify total decompaction, myelin sheaths were rated as compacted or decompacted, as 
defined by the presence or absence of fibers with disruption of the myelin sheath (i.e. 
decompacted = presence of areas with splitting of myelin lamellae). To measure severity of 
decompaction, we analyzed each quartile of each fiber (4 measurements per myelinated 
axon cross section), and report results as 1, 2, 3, or 4 quadrants showing decompaction 
(color coded in figures 3–6). The g-ratio of myelinated fibers was obtained by dividing the 
diameter of each axon by the fiber diameter (300–500 axons/mouse, n=3–5 mice/genotype/
condition), using ImageJ software. When a fiber was identified as compact, or showed 4 
quadrants decompacted, 1 measurement was collected for g-ratio. However, if a fiber 
showed 2 quadrants decompacted, then 2 measurements were collected, perpendicular to 
each other; if a fiber showed 1 or 3 quadrants decompacted, 4 measurements at 90° angles 
were collected for measurement of myelin thickness. Measurement was carried out by 
individuals blinded to sample identify and treatment.
Flow Cytometry
Adult murine brains were processed for flow cytometry as described (Robinson et al. 2014). 
Flow cytometry was performed using FacsDiva software for acquisition on an LSR II flow 
cytometer. We used antibodies recognizing oligodendrocyte progenitors (PDGFRα 1:50; 
Millipore), and mature oligodendrocytes (GalC 1:100; Millipore). An ENZO Life Sciences 
kit was used to detect Nitric Oxide (ENZ-51013-200). Importantly, a positive control (L-
arginine, a nitric oxide synthase substrate) and a negative control (C-PTIO, a nitric oxide 
scavenger) validated staining specificity for nitric oxide (Kalyanaraman et al. 2012). 
Titus et al. Page 4













Analysis was performed using FlowJo10 software. Compensation was carried out using 
positive and negative controls, as well as Fluorescence Minus One (FMO) samples, which 
were dissociated forebrain cells incubated with all stains except the marker of interest, to 
allow for appropriate compensation.
Drug Treatments
Gamma secretase inhibitor (GSI; MRK-003) was prepared fresh weekly and dosed at 300 
mg/kg in 0.5% methocel by oral gavage (Lewis et al. 2007; Sparey et al. 2005). For 
histology, we dosed mice once weekly for 4 weeks, and sacrificed them 6 hours after the last 
dose (n=5 doses). Fresh solution of L-NG-Nitroarginine Methyl Ester (L-NAME) at 
0.4mg/kg (100µM in 1× PBS) was administered daily. For pathology and flow analysis, mice 
were injected intraperitoneally (IP) daily with 100µL for 7 days and sacrificed 6 hours after 
the last dose. MEK inhibitor (PD0325901 from Pfizer) was made fresh weekly and dosed at 
1.5 mg/kg in 0.5% methocel/0.2% Tween 80 by oral gavage. For histology, we dosed mice 
every day for 3 weeks.
Statistical Analysis
The minimal number of independent experiments/mice per statistically significant 
experiment was 3. Comparison between two groups used Student’s t-tests with significance 
cutoff of p<0.05. For comparison of three or more groups, one-way ANOVA followed by 
Tukey post hoc test with significance cutoff of p<0.05. Linear regression of g-ratio vs. axon 
diameter was performed using Graph Pad software.
Results
RasG12V Mutation in Mature Oligodendrocytes Activates MAPK Signaling Without 
Affecting Oligodendrocyte Numbers
To study how the CS mutation HRasG12V affects myelinating mOLs, we induced the 
expression of HRasG12V from the Ras endogenous locus. Mice carrying the mutant allele 
HRasG12V downstream of the endogenous HRas gene flanked by loxP sites (Chen et al. 
2009) were crossed with mice carrying a tamoxifen-inducible Cre recombinase under the 
transcriptional regulatory elements of proteolipid protein 1 (Plp1CreERt2) (Doerflinger et al. 
2003). In these mice, tamoxifen treatment induces the expression of HRasG12V upon 
excision of the endogenous HRas (Fig. 1A). Recombination using this PlpCre driver targets 
~35% of mOLs in the corpus callosum (CC), and essentially no NG2+ oligodendrocyte 
progenitors or GFAP+ astrocytes are recombined (Koenning et al. 2012; Mayes et al. 2013). 
Numerous studies indicate that diverse phenotypes are caused by varying levels of Ras-
MAPK activation (Cox and Der 2003; Serrano et al. 1997). With respect to myelin defects, 
decreasing gene-dose of Nf1, a negative regulator of Ras, correlates with progressively 
increasing levels of decompaction (López-Juárez et al. 2017); therefore, we studied both 
HRasG12V homozygous and hemizygous mutants. Adult (>8 week old) hemizygous 
PlpCreERt2;HRasG12V/+ (henceforth pRsG/+) and homozygous PlpCreERt2;HRasG12V/G12 
(henceforth pRsG/G) RasG12V mutants, as well as control PlpCreERt2 or RasG12V/+ 
littermates, were treated with tamoxifen, and analysis of the CC at different time points was 
performed. No phenotypic differences were observed between control PlpCreERt2 and 
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pRasG12V/+ mice (henceforth referred as wild type; WT) and, in agreement with a previous 
report (Doerflinger et al. 2003), we did not observe spontaneous activity of PlpCreERt2. We 
confirmed Ras hyper-activation specifically in mOLs by assessing the presence of the 
phosphorylated form of ERK (pERK), a downstream target of Ras-GTP, in cells stained with 
the mOL marker CC1 (Fig. 1B). The number of CC1+ mOLs in the CC of RasG12V mutants 
was not significantly different from that in WT mice (Fig. 1C). In contrast, significantly 
increased numbers of pERK+CC1+ mOLs were detected in pRsG/G and pRsG/+ mutants 1 
month after tamoxifen treatment (Fig. 1D). We note that high variability in the number of the 
pERK+;CC1+ mOLs occurred in homozygous RsG12V mutants, yet specific induction of 
hyperactive Ras was achieved in both Ras mutants.
Constitutive HRas Activation in Mature Oligodendrocytes Decreases g-ratio
To study WM abnormalities after Ras activation, we analyzed the ultrastructure of axons and 
myelin in sagittal sections at the midline of the CC of RasG12V mutants using electron 
microscopy (Fig. 2A). Unbiased counting of myelinated axons revealed significantly 
decreased g-ratio in pRsG/+ and pRsG/G mutants 1 month post-tamoxifen treatment, as 
compared to WT mice (Fig. 2B). We did not count numbers of small unmyelinated axons; 
however, numbers of large caliber unmyelinated axons in the CC did not change with 
genotype (n= 3 mcie/genotype, one-way ANOVA p=0.057, with Tukey’s multiple 
comparison test WT vs, pRsG/+; 0.072; WT vs, pRsG/G; p=0.093). Further, decreases in g-
ratio were observed in both mutants at 6 months post-tamoxifen (Fig. 2B), indicating that 
the decrease in g-ratio is progressive. One month post tamoxifen, low g-ratio was not 
preferentially associated to small or large diameter axons, as indicated by linear regression 
analysis of g-ratio vs. axon diameter in mutant vs WT mice (Fig. 2C). However, at six 
months post-tamoxifen, an increased association of low g-ratio with small caliber axons was 
observed in both homozygous and hemizygous HRasG12V mutants as compared to WT 
mice (Fig.2D); indicating that small caliber axons contribute to progressive abnormal g-
ratio, and/or axons shrink over time (Fig. 2B). Myelinating cells regulate axon caliber (Cole 
et al. 1994; Colello et al. 1994), so myelin defects caused by HRas activating mutation in 
mOLs might disrupt axon structure. In fact, quantification of myelinated axon diameter 
indicated a significant skew to decreased axon diameter in both pRsG/+ and pRsG/G 
mutants, as compared to WT (Fig. 2E). As neurons whose axons project through the CC do 
not express the PlpCre allele (Koenning et al. 2012; Mayes et al. 2013), change in axon 
diameter is likely to be secondary to disturbed myelin integrity (Cole et al. 1994; Colello et 
al. 1994), thus we focused on the analysis of the myelin structure.
Hyperactivation of HRas in Mature Oligodendrocytes Results in Myelin Decompaction
The MAPK signaling pathway regulates numbers of myelin wraps as well as compaction of 
myelin in mOLs (Ishii et al. 2013, López-Juárez et al. 2017). We observed that myelin 
thickness was increased in RasG12V mice, as both homozygous and hemizygous mutants 
displayed myelin decompaction at intraperiod lines (Fig. 2A, arrows), without showing 
changes in the number of myelin lamellae wrapping axons (Fig. 3A). Therefore, the two 
parameters determining g-ratio, axon diameter and myelin thickness, were abnormal in 
HRas mutants. Quantification of the fibers showing decompaction indicated a significant 
increase in the percent of myelin sheaths with decompaction in both RasG12V mutants 1 
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month after tamoxifen treatment, as compared to WT mice (Fig. 3B). This phenotype was 
sustained for at least 6 months post-tamoxifen with no obvious worsening of decompaction. 
To determine changes in the severity of myelin decompaction, we divided myelinated fibers 
into quadrants and reported the percent of fibers showing decompaction in 1, 2, 3 or 4 
quadrants around each axon. We corroborated similar decompaction patterns in both 
RasG12V mutants over time (Fig. 3B, bottom; color code). Thus, hyperactivation of HRas in 
mOLs disrupts myelin structure within 1 month, and this phenotype is sustained, while the 
non-cell-autonomous effects on axons appear progressive. Next, we analyzed whether small 
or large diameter axons preferentially show myelin decompaction. As shown in figure 3C, 
small myelinated axons (<0.9 µm) of homozygous and hemizygous HRas mutants, and 
medium caliber myelinated axons (0.91 – 1.2 µm) of homozygous mutants, were affected by 
myelin decompaction 1 month post-tamoxifen. These results indicate that myelin 
decompaction impacts small caliber axons in the short-term and may cause axon shrinkage 
over time (Fig. 2B–E). As hemizygous HRasG12V mutation most closely models CS 
patients, we focused additional study on the analysis of signaling pathways controlling 
myelin decompaction in pRsG/+ mutants.
Myelin Decompaction is Partially Rescued by Inhibition of MEK or NOS, and Full Rescue is 
Achieved by the Concomitant Treatment in Hemizygous HRas Mutants
In order to gain insight into molecular mechanisms driven by HRas activating mutations that 
affect oligodendrocytes, we first evaluated the effect of blocking MEK, the major effector 
pathway downstream of Ras-GTP in Rasopathies. We analyzed myelinated fibers in the CC 
of mice treated with the blood brain barrier-permeable MEK inhibitor (MEKi) PD0325901, 
starting 1 month post-tamoxifen (Barrett et al. 2008). Administration of MEKi did not 
significantly change myelin decompaction in WT mice, although a trend toward increased 
decompaction was observed (Fig. 4A). Likewise, no differences in g-ratio were observed 
between vehicle-treated WT and MEKi-treated mice (Fig. 4B). MEKi treatment slightly 
improved compaction in pRsG/+ mutants, as compared to vehicle-treated mutants, but this 
was not significant (Fig. 4A). In contrast, MEKi significantly normalized g-ratio in pRsG/+, 
however full recovery to WT levels was not achieved (Fig. 4B). These results indicate that 
MEKi, at a therapeutically relevant dose, does not fully rescue myelin defects caused by 
HRasG12V in mOLs. We therefore searched for additional effectors downstream of Ras.
It was previously reported that myelin defects resulting either from activation of HRas in the 
oligodendrocyte lineage, or from inactivating the Ras regulator Nf1 in mOLs, can be 
partially rescued by blocking the production of Nitric Oxide in vivo (López-Juárez et al. 
2017; Mayes et al. 2013). Therefore, we first tested whether NO signaling is abnormally 
increased in pRsG/+ mutants at a time point when myelin defects are evident. We 
dissociated cells from the forebrain of WT and pRsG/+ mice and stained them with cell-type 
markers as well as a dye that emits fluorescence in the presence of NO. Flow cytometry 
analysis revealed that the number of GalC+ mOLs showing staining for NO dye was 
significantly increased in the pRasG12V mutants as compared to WT mice, while the 
number of PDGFRa+;NO+ oligodendrocyte precursors remained unchanged (Fig. 4C). 
Therefore, we evaluated myelin defects in pRasG12V hemizygous mutants treated with L-
NAME, an inhibitor of NO synthases, starting at 1 month post-tamoxifen. L-NAME 
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treatment caused a significant decrease in the number of fibers with decompaction in the CC 
of pRsG/+ mice (Fig. 4A) and a significantly increased g-ratio (Fig. 4B), as compared to 
vehicle-treated Ras mutants. However, neither myelin compaction nor g-ratio were fully 
restored to WT levels.
To determine whether the combination of NOS and MEK inhibition provides an additive 
benefit, we assessed myelin properties in pRsG/+ mutants treated with MEKi and L-NAME 
and found that pathologic myelin decompaction was abolished (Fig. 4A). In fact, under these 
conditions, myelin was more compact than in untreated WT CC, and g-ratio was increased 
over the levels observed in WT mice (Fig. 4B); suggesting that basal MAPK-NO signaling 
contributes to the maintenance of normal compact myelin. Taken together, these data show 
that disturbed MAPK and NO signaling cooperate to disrupt myelin structure upon 
HRasG12V expression.
Inhibition of Notch Signaling Rescues Myelin Defects in Hemizygous HRasG12V Mutants
We recently reported that myelin defects in a model of NF1 Rasopathy result in part from 
abnormal hyper-activation of Notch in mOLs, and that mice overexpressing the Notch 
Intracellular Domain (the active form of Notch that translocates to the nucleus) show 
disrupted myelin compaction and a reduced g-ratio (López-Juárez et al. 2017). Therefore, 
we hypothesized that myelin abnormalities in pHRasG12V mutants may also require Notch 
activation. We used the tamoxifen-inducible allele Rbpjfl/fl to inactivate recombining 
binding protein suppressor of hairless (RBPJ), the essential transcriptional co-factor for 
canonical Notch signaling, in pRsG/+ mutants. Analysis of myelinated axons in the CC of 
PlpCreERt2;HRasG12V/+;Rbpjfl/fl (henceforth pRsG/+;pRBPJ) mutants showed only a trend 
toward a decrease in the percent of decompacted fibers at 1 month post-tamoxifen treatment, 
versus pRsG/+ mutants (Fig. 5A). Similarly, no significant differences were found between 
the g-ratio of pRsG/+;pRBPJ and pRsG/+ mutants (Fig. 5B).
Upon Notch ligand binding, active NICD is released by the action of Gamma secretase. 
Therefore, inhibition of this enzyme prevents Notch signaling. As a secondary strategy to 
evaluate the Notch pathway contribution to abnormal myelin in pRasG12V mutants, we 
treated mice with Gamma secretase inhibitor (GSI). Analysis of CC myelinated axons 
revealed a significant decrease in the number of fibers with decompaction (Fig. 5C) and an 
increase in g-ratio (Fig. 5D) in GSI-treated pRsG/+ mutants as compared to vehicle-treated 
pRsG/+ mice. Although the rescue of the phenotypes was not to the level of WT mice, these 
data support participation of Notch signaling downstream of RasG12V mutation. The 
different level of rescue observed in RBPJ loss model and GSI treatment (compare Fig. 5A–
C and 5B–D) may include compensation for the absence of RBPJ in mOLs, GSI effects on 
cells in addition to mOLs, and/or effects of GSI on other γ-secretase substrates (Langosch et 
al. 2015).
Concomitant Inhibition of Notch Signaling and MAPK or NO Signal Pathways Fully 
Rescues Myelin Abnormalities in HRasG12V Mutants
Given that neither treatment with MEKi, nor treatment with L-NAME, fully rescued myelin 
compaction in pRsG/+ mutants, and that blocking both pathways fully rescued the 
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phenotypes, we tested whether inhibition of Notch pathway lead to additive effects on 
myelin structure. We evaluated myelinated axons in the CC of pRsG/+;pRBPJ double 
mutants after treatment with MEKi or L-NAME. The combination of inducible genetic 
Notch inactivation with MEKi treatment decreased myelin decompaction significantly, to 
levels observed in WT mice (Fig. 6A). Fiber g-ratio was significantly improved in pRsG/
+;pRBPJ double mutants treated with MEKi as compared to vehicle-treated mice of the 
same genotype (Fig. 6B). However, this combination did not improve g-ratio more than 
MEKi treatment alone, possibly because non-cell autonomous effects on axon diameter are 
not affected by pRBPJ mutation in mOLs (Fig. 2C).
Additionally, pRsG/+;pRBPJ double mutant mice treated with L-NAME showed improved 
myelin compaction (Fig. 6C). Furthermore, g-ratio improved to WT levels (Fig. 6D). 
Overall, these data support the idea that myelin decompaction caused by increased levels of 
Ras-GTP can be restored through use of combinations of drugs targeting MAPK, NO, and/or 
Notch. However, rescue of g-ratio occurs only with the combination of drugs targeting both 
MAPK and NO. Taken together, our results suggest that pharmacological tools targeting 
MAPK, NO, and/or Notch signal pathways, alone or in combinations, may ameliorate CNS 
manifestations in Costello Syndrome.
Discussion
RAS regulators, RAS effectors, and RAS proteins themselves can be mutated in Rasopathies 
and are the subject of intensive research, with new mutations still being detected (Tidyman 
and Rauen 2016). Precisely how increases in active RAS-GTP impair brain function is still 
poorly understood. In CS, as in many Rasopathies, hyperactive Ras signaling can cause 
neurodevelopmental abnormalities, including cognitive impairment, autism spectrum 
disorders, and white matter abnormalities. Here we report that the Ras-activating mutation 
HRasG12V, conditionally expressed in the endogenous H-Ras locus, causes pathological 
myelin decompaction mediated by MAPK, Nitric Oxide, and Notch signaling.
Strong evidence supports the idea that overexpression of mutant RAS can result in altered 
localization and cellular responses, versus RAS-GTP activated physiologically (Di 
Nicolantonio et al. 2008; Quinlan et al. 2008; Sarkisian et al. 2007). This is thought to result 
because local regulatory elements control RAS expression and downstream effects within 
tissues (To et al. 2008). Therefore, use of the HRasG12V in its endogenous locus should 
accurately mimic cell autonomous effects of the Costello mutation in OL. Previously we 
reported myelin decompaction in a transgenic CNP-HRasG12V model, in which HRasG12V 
is expressed in developing OPCs and oligodendrocytes (Mayes et al. 2013). Our new study 
of HRasG12V induction in its endogenous locus in mOLs, confirms a role of hyperactive 
HRas in pathological myelin decompaction and, importantly, shows the onset of this 
phenotype in mature OLs of the adult mouse, rather than in developmental stages with lower 
potential for therapeutics. While HRasG12V is a rare mutation associated with severe 
manifestations in CS patients (Aoki et al. 2005), experimental G12V mutation mimicked 
phenotypes found in models of the most common HRas mutation (G12VS) (Rooney et al. 
2016).
Titus et al. Page 9













Several studies using gain and loss of function models have shown that the RAS effectors 
ERK1 and ERK2 promote the establishment and maintenance of myelin thickness, 
regulating both the number of myelin wraps and the abundance of major myelin proteins 
(Fyffe-Maricich et al. 2011; Fyffe-Maricich et al. 2013; Guardiola-Diaz et al. 2012; Ishii et 
al. 2013). In contrast, we show that HRasG12V expression in mOL causes myelin 
thickening due to pathological myelin decompaction, without an increase in the number of 
myelin lamellae. Myelin decompaction was also reported in the CNP-HRasG12V mouse 
model in which changes in expression of tight junction, not myelin, proteins were observed 
(Mayes et al. 2013). Differences in myelin phenotypes may be due to the mutants analyzed 
and their effects on levels of RAS activation. Mechanistically, Ras-GTP activation of ERK1/
ERK2 activates feedback regulation that dampens or enhances Ras signaling (Rauch et al. 
2016). For example, the Ras-MAPK negative regulator Sprouty 2, induced on growth factor 
stimulation through MAPK, is highly expressed in the brain, where it dampens the impact of 
MAPK pathway activation in germline-HRasG12V mutants. Strong activation of MEK/ERK 
is observed in the liver of the same mice, where Sprouty2 is virtually absent (Chen et al. 
2009). This is important because high levels of Ras-MAPK activation mediate cell 
senescence and apoptosis, while lower levels alter cell proliferation and differentiation (Cox 
and Der 2003; Serrano et al. 1997). Therefore, differences in feedback regulation in cells 
with Ras activation differ from those with direct MEK/ERK activation. In addition, RAS-
GTP activates multiple effector cascades parallel to MAPK activation, which may contribute 
to decompaction in Ras but not in MEK or ERK mutants.
Based on this and previous studies, maintenance of myelin compaction is controlled by Ras-
MAPK. Thus, HRasG12V expression or Nf1 mutation in mOLs causes decompaction in 
previously myelinated fibers (López-Juárez et al. 2017). However, once a maximum level of 
decompaction is reached (60–75% of total myelinated fibers), no further increase is 
observed over time. This result suggests that adhesion systems may maintain this residual 
compaction. Compact myelin proteins such as Claudin 11, proteolipid protein, and connexin 
32 (Gielen et al. 2006; Martini and Schachner 1997) are likely to be involved. It is also 
possible that as-yet-unidentified signaling pathways contribute to maintaining myelin 
compaction. Additional phenotypes caused by HRas mutation in mOLs, such as axon caliber 
decrease, appear to be non-cell-autonomous effects and show slower progression.
We directly show elevated NO in pRsG/+ mOLs, consistent with roles for Ras-NO signaling 
in the myelin decompaction phenotype and supporting the involvement of this signal 
downstream of HRasG12V expression. Notably, in CNP-HRasG12V mice behavioral 
abnormalities were rescued by blocking NO generation using L-NAME (Mayes et al. 2013). 
In ex-vivo brain preparations, Ras signaling through MEK/ERK also increased reactive 
oxygen/nitrogen species, and NO protected oligodendrocytes through inhibition of 
nitrotyrosine-induced ERK phosphorylation (Heimfarth et al. 2013). At higher levels, NO 
can be toxic; suppressing myelin gene transcription, translation of myelin proteins (Jana and 
Pahan 2013), and promoting apoptosis (Li et al. 2011). In pRsG/+ mOLs, while inhibition of 
NO production decreased myelin decompaction, additionally targeting MEK was able to 
fully rescue the myelin phenotype. Why both inhibitors are necessary in pRsG/+ mOLs 
remains unclear; it may result from vertical inhibition (e.g. the additive impact of blocking 
two members of the same signaling pathway) and/or from blocking pathway crosstalk.
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In mOLs lacking the Nf1 Rasopathy gene, thereby activating RAS-GTP, NO links MAPK 
and Notch signaling (López-Juárez et al. 2017). Our data support a role for Notch signaling 
in mOLs, but in HRasG12V mOL the evidence is less robust than for the Nf1 model. Thus, 
while we demonstrate a trend toward improvement in myelin compaction in HRasG12V 
mice lacking Rbpj, the effect is not significant (unlike in the Nf1 setting). Additionally, 
given that gamma secretase has at least 90 substrates, the effects of GSI, while significant, 
cannot be taken as specific to inhibition of Notch signals. Yet, Rpbj loss in HRasG12V mice, 
sensitized mutant cells to MEK or NOS inhibition, supporting the view that Notch signaling 
is relevant in this model. It may be that levels of active Notch in HRasG12V mice are low, 
and/or that feedback interaction between the Ras-MAPK and the Notch pathway occurs; 
possibly through decreasing activity of one increasing dependence on the other. In either 
event, our results indicate that Ras and Notch signals are involved in myelin compaction.
We observed consistent “more-than-complete” rescue of phenotypes following 
combinatorial drug treatments in HRasG12V hemizygous mutants. This effect was shown 
previously for myelin decompaction in Nf1 and CNP-HRas mOL mice treated with 
inhibitors (López-Juárez et al. 2017; Mayes et al. 2013). This response could result from off 
target activity of pharmacological tools. We support the alternative explanation that 
combination treatments overshoot dose(s) needed for optimal rescue. If this is the case, 
expression of Rasopathy genes, including HRasG12V, uncover signaling pathways that 
maintain normal myelin compaction by balancing levels MAPK, NO and Notch. 
Relationships between MEK-NOS-Notch pathways controlling normal and pathological 
myelin in a cell-autonomous manner are likely to be complex, and future studies will need to 
consider titering levels of response to optimize inhibitor effects in specific settings. 
Furthermore, non-cell-autonomous activation of these pathways seems to add complexity to 
the system. Recombination is elicited by the PlpCreER driver in about 35% of mature carpus 
callosum oligodendrocytes (Koenning et al. 2012, Mayes et al., 2013). In contrast, 
decompaction is observed in ~60–70% of myelinated fibers, making it unlikely that only 
recombinant oligodendrocytes show abnormal myelin. In previous studies (Mayes et al. 
2013, López-Juárez et al. 2017), as well as in this study, we show data supporting the idea 
that non-cell-autonomous effects are mediated at least in part by a diffusible signal, NO.
In summary, MEK, NOS, and gamma secretase inhibitors each partially rescue aberrant 
myelin decompaction in a Costello Syndrome Rasopathy model. It will be interesting to 
determine whether myelin alterations are present in Costello Syndrome patients, in whom 
many (in somatic mosaic patients) or all (in germline heterozygotes) brain cells are 
heterozygous for HRAS activating mutations. Lastly, clinical trials are ongoing in many 
disorders in which MAPK, NO, and Notch signals are targeted/impacted; therefore, in the 
case of Rasopathies, treatment trials using inhibitors of these pathways are feasible.
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• In a Costello syndrome model, HRasG12V expression in mature 
oligodendrocytes activates the MAPK pathway, causing myelin 
decompaction.
• Combining inhibition of any two pathways, of MAPK, Nitric Oxide and 
Notch signaling, rescues myelin defects.
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FIGURE 1. RasG12V mutation in mature oligodendrocytes activates MAPK pathway without 
affecting oligodendrocyte numbers
A: Schematic representation of the genomic region containing the endogenous HRas gene in 
PlpCreERt2;HRasG12V mice (pRsG12V). Left: the WT HRas gene (cyan) flanked by loxP 
sites [exons 1–4 (Chen et al. 2009)] is localized upstream of the mutant HRasG12V gene 
(purple). Right: following tamoxifen administration, active Cre recombinase mediates the 
excision of WT HRas, allowing the expression of the mutant HRasG12V allele from the 
HRas locus. The mutant allele is not expressed unless the WT copy is excised. B: Corpus 
callosum (CC) of WT mice (top), hemizygous (middle), and homozygous (bottom) 
pRsG12V mutants, one month (1mo) after tamoxifen treatment showing staining for the 
marker of mature oligodendrocytes CC1 (green), the phosphorylated form of ERK (pERK, 
red), and overlap (right column). Positive cells for both markers are indicated with arrows 
within the insets from the squared areas. St: striatum. C: Quantification of CC1+ cells 
indicates no differences in the number of oligodendrocytes in pRsG/+ (n= 6 mice, unpaired t 
test, p=0.66) or pRsG/G (n= 3 mice, unpaired t test, p=0.31) mutants, as compared to WT 
mice (n= 9 mice). D: Quantification of CC1+;pERK+ cells indicates significantly increased 
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ERK activation in oligodendrocytes of pRsG/+ (n= 6 mice, unpaired t test, **p=0.002) or 
pRsG/G (n= 3 mice, unpaired t test, *p=0.034) mutants, as compared to WT mice (n= 9 
mice). All data are presented as the mean ± s.e.m.
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FIGURE 2. HRas hyperactivation in mature oligodendrocytes decreases g-ratio
A: Electron micrographs of myelinated axons in the corpus callosum (CC) at the midline of 
WT, pRsG/+, and pRsG/G mice 1 month after tamoxifen treatment. High magnifications 
(50,000×) are shown at right; regions with myelin decompaction (See also figure 3A) are 
indicated with arrows. B: Analysis of only myelinated axons indicates decreased g-ratio in 
pRsG/+ and pRsG/G mutants at 1 month (1mo, n= 3 mice per genotype) and 6 months (6mo, 
pRsG/+ mice; n= 5, pRsG/G mice; n= 3 mice) post-tamoxifen (****p<0.0001), as compared 
to g-ratio in WT mice (n= 6 mice). The g-ratio was further decreased in pRsG/+ and pRsG/G 
mutants at 6 months post-tamoxifen, as compared to pRsG/+ and pRsG/G mice 1 month 
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after tamoxifen (####p<0.0001), respectively. C–D: Scatterplots and linear regression of the 
axon diameter vs. g-ratio from myelinated fibers in WT (black), pRsG/+ (pink), and pRsG/G 
(green) mice, 1 month (C) and 6 months (D) after tamoxifen treatment. The slopes of g-ratio 
vs. axon diameter are similar in HRas mutants compared to WT mice at 1 mo (C, black 
arrow); however, small g-ratio in HRas mutants is associated to small diameter axons at 6 
mo (D, black arrow vs. red arrow). E: Evaluation of the diameter of myelinated axons shows 
significant decreases in pRsG/+ (n= 3 mice, **p=0.001) and pRsG/G (n= 3 mice, 
****p<0.0001) 1 month after tamoxifen treatment, as compared to WT mice. One way 
ANOVA and Tukey’s multiple comparisons test was used in the analyses. All data are 
presented as the mean ± s.e.m.
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FIGURE 3. HRas hyperactivation in mature oligodendrocytes causes myelin decompaction
A: Left: Representative image of the number of myelin lamellae (triangles) wrapping an 
axon in WT and pRsG/+ mice. Right: quantitative analysis indicates no significant changes 
in the number of myelin wraps between WT and pRsG/+ mice (unpaired t test, p=0.64). B: 
Analysis of myelinated axons indicates significantly increased percent of fibers with myelin 
decompaction in pRsG/+ mutants at 1 month (1 mo, n= 3 mice, ****p=0.0001) and 6 
months (6 mo, n= 5 mice, ***p=0.0006) post-tamoxifen, compared to WT mice (n= 3 mice). 
Myelin decompaction was also observed in pRsG/G mutants at 1 mo (n= 3 mice, 
***p=0.0009) and 6 mo (n= 3 mice, ***p=0.0005) post-tamoxifen, as compared to WT 
mice. No significant changes were observed among different time points in both pRsG12V 
mutants. The percent of fibers showing decompaction in 1–4 quadrants (color code; bottom) 
is shown within the total fibers with decompaction, as a reference for severity of the 
phenotype. C: Significantly increased percent of decompacted myelin was detected in fibers 
containing small axons (<0.9 µm, n= 3 mice, **p=0.001) in pRsG/+ mutants, and small (n= 
Titus et al. Page 20













3 mice, *p=0.037) and medium (0.91–1.2 µm, n= 3 mice, *p=0.048) axons of in pRsG/G 
mutants 1 month post-tamoxifen, as compared to WT mice (n= 6 mice). One way ANOVA 
and Tukey’s multiple comparisons test was used in all analyses, except in panel A (Student’s 
t test). All data are presented as the mean ± s.e.m.
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FIGURE 4. Myelin defects in pRsG/+ mutants are susceptible to MEK and NOS pharmacological 
inhibition
A: Quantification of total fibers with myelin decompaction, and quadrants with 
decompaction (color code), in WT and pRsG/+ mutants subjected to the indicated 
pharmacological treatments 1 month post-tamoxifen. No significant changes (but a trend 
toward increase) are observed in the percent of decompacted fibers in MEK inhibitor 
(MEKi)-treated WT (n= 6), as compared to vehicle-treated WT mice (n= 3, ns: not 
significant, p=0.219). Vehicle-treated pRsG/+ mutants (n= 3) show increased myelin 
decompaction, as compared to vehicle-treated WT mice (methocel for MEKi; **p=0.002 
and PBS for L-NAME; **p=0.003). No significant changes (but a trend toward decrease) 
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were observed in decompaction in pRsG/+ mutants treated with MEKi (n= 3 mice), as 
compared to vehicle-treated mutants (ns, p=0.261). Significantly decreased percent of 
decompacted fibers were observed in pRsG/+ mutants treated with L-NAME (n= 4 
mice, $p=0.030), and myelin compaction was fully rescued to WT levels by concomitant 
treatment with L-NAME and MEKi, as compared to vehicle-treated mutants (n= 4 
mice, ####,$$$$p<.0001). B: The g-ratio comparison of WT and pRsG/+ mutants subjected to 
the indicated pharmacological treatments 1 month post-tamoxifen (same cohort of mice as in 
panel A). No significant changes were observed in g-ratio of vehicle-treated vs. MEKi-
treated WT mice (ns, p=0.996). Vehicle-treated pRsG/+ mutants show decreased g-ratio, as 
compared to WT mice (PBS or methocel ****p<0.0001). Significantly increased g-ratio was 
observed in pRsG/+ mutants treated with MEKi (####p<0.0001) or L-NAME 
($$$$p<0.0001), as compared to vehicle-treated mutants, respectively. Furthermore, 
increased g-ratio was observed in pRsG/+ mutants concomitantly treated with MEK and L-
NAME (####,$$$$p<0.0001). C: Flow cytometry analysis of forebrain cells indicates no 
change in the number of PDGFRa+ OL precursors showing Nitric Oxide (NO) signals (ns, 
p=0.225); however, the number of GalC+;NO+ mOLs are significantly increased in pRsG/+ 
mutants (n= 3 mice, t test, *p=0.042), as compared to WT mice (n= 3 mice). Data are 
presented as the mean ± s.e.m. One-way ANOVA and Tukey's multiple comparisons test 
were used in all panels, except in C.
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FIGURE 5. Effects of Notch signaling inhibition on myelin defects in HRasG12V mutants
Quantification of total fibers with myelin decompaction and quadrants with decompaction 
(panels A and C), and g-ratio evaluation (panels B and D), in WT (n= 6 mice), pRsG/+ (n= 3 
mice), pRsG/+;pRBPJ (n= 5 mice), and GSI-treated pRsG/+ (n= 6 mice) mice, 1 month 
post-tamoxifen. A: No significant changes (but a trend toward decrease) were observed in 
the percent of decompacted fibers in pRsG/+;pRBPJ mutants, as compared to pRsG/+ mice 
(ns, p=0.091). B: No significant changes were observed in the g-ratio of pRsG/+;pRBPJ 
mutants, as compared to pRsG/+ mice (ns, p=0.086). C: Significantly decreased percent of 
decompacted fibers was observed in GSI-treated pRsG/+ mutants, as compared to vehicle-
treated pRsG/+ mice (*p=0.011). D: A significant increase in g-ratio was detected in GSI-
treated mutants, as compared to pRsG/+ mice (ns, p<0.0001). In all panels; WT values are 
shown for reference, One-way ANOVA and Tukey's multiple comparisons test were used, 
and data are presented as the mean ± s.e.m.
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FIGURE 6. Concomitant inactivation of RBPJ and MEK or NOS pharmacological inactivation 
fully rescues myelin abnormalities in HRasG12V mutants
Quantification of total fibers with myelin decompaction and quadrants with decompaction 
(panels A and C), as well as g-ratio evaluation (panels B and D), in WT, pRsG/+, and pRsG/
+;pRBPJf/f mice treated with vehicle, MEKi, or L-NAME, 1 month post-tamoxifen. A: Full 
rescue of myelin compaction to WT levels (WT; n= 6 mice, p=0.938) was observed in pRsG/
+;pRBPJf/f mice treated with MEKi (n= 3 mice), as compared to pRsG/+ mice (n= 4 mice, 
*p=0.031). B) The g-ratio was significantly increased in MEKi-treated pRsG/+;pRBPJf/f 
mutants, as compared to vehicle-treated pRsG/+ mice (****p<0.0001); however, the g-ratio 
was still significantly lower than those in WT mice (**p=0.007). C: Significantly decreased 
myelin decompaction was observed in pRsG/+;pRBPJf/f mice treated with L-NAME (n= 3 
mice), as compared to pRsG/+ mice (n= 6 mice, *p=0.021), and the values of decompaction 
were not significantly different than those of WT mice (ns, p=0.888). D) The g-ratio was 
significantly increased in L-NAME-treated pRsG/+;pRBPJf/f mutants, as compared to 
vehicle-treated pRsG/+ mice (****p<0.0001), and g-ratio was not different from those of 
WT mice (ns, p=0.057). In all panels, One-way ANOVA and Tukey's multiple comparisons 
test was used and data are presented as the mean ± s.e.m.
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Table 1
Mouse strains used in this study
Genotype Description Abbreviation Reference
B6.Cg-Tg(Plp1-Cre/ERT)3Pop/J Tamoxifen Inducible Cre 
recombinase under the transcriptional 
control of the mOL marker Plp1
PlpCreER Doerflinger et 
al., 2003
FR-HrasG12V Mutant HRasG12V allele upstream of 
WT HRas flanked by loxP sites
HRasG12V Chen et al., 
2009
RBP-Jflox Endogenous rbpj gene flanked by 
loxP sites
Rbpjflox Han et al., 2002
B6.Cg-Tg(Plp1-Cre/ERT)3Pop/J; FR-HrasG12V Tamoxifen administration mediates 
excision of endogenous (WT) HRas 
and expression of the mutant 
HRasG12V allele.
pRsG/+ or pRsG/G --
B6.Cg-Tg(Plp1-Cre/ERT)3Pop/J; FR-HrasG12V;RBP-Jflox Tamoxifen administration mediates 
excision of endogenous (WT) HRas, 
expression of the mutant HRasG12V 
allele and inactivation of Rbpj.
pRsG/+;pRbpj --
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